Detalles de la búsqueda
1.
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Br J Cancer
; 130(2): 224-232, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37973958
2.
Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Int J Clin Oncol
; 24(2): 222-230, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30244364
3.
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Cancer Chemother Pharmacol
; 88(3): 543-553, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117512
4.
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
BMJ Open
; 10(12): e041737, 2020 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33334838
5.
Protocol of a randomised controlled trial on the efficacy of medication optimisation in elderly inpatients: medication optimisation protocol efficacy for geriatric inpatients (MPEG) trial.
BMJ Open
; 10(10): e041125, 2020 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33046478
6.
Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.
J Clin Oncol
; 36(10): 1000-1006, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29443652
Resultados
1 -
6
de 6
1
Próxima >
>>